Results 141 to 150 of about 529,483 (274)

Guselkumab as a treatment option for recalcitrant pyoderma gangrenosum

JAAD Case Reports, 2021
Cassandra Baier, MS, PA-C, Orr Barak, MD, PhD   +1 more
doaj   +1 more source

A meta-analysis of immunosuppressive and Pharmacological therapies in aplastic anaemia with and without Indigenous equine antithymocyte globulin (eATG). [PDF]

Ann Hematol
George B, Ross CR, Damodar S, Seth T, Dolai TK, Banerjee S, Manguesh R, Malhotra P.   +7 more
europepmc   +1 more source

2026 Update on the Management of Diffuse Large B‐Cell Lymphoma

American Journal of Hematology, EarlyView.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) is the most common type of NHL in the Western Hemisphere. It comprises a heterogenous group of lymphomas, with different biology and clinical prognoses. R‐CHP remains the backbone of therapy, and frontline therapeutic options in fit patients are pola‐R‐CHP and R‐CHOP, whereas elderly or frail/unfit ...
Elise A. Chong, Emily B. Tomasulo, Stefan K. Barta   +2 more
wiley   +1 more source

Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma

Hepatology, EarlyView., 2022
Steatotic HCC can be diagnosed by MRI and forms a pro‐tumor immune microenvironment with high expression of PD‐L1, M2 polarization of macrophages and activation of CAFs, which may be a good target for combined immunotherapy. Abstract Background and Aims Immunotherapy has become the standard‐of‐care treatment for hepatocellular carcinoma (HCC), but its ...
Hiroki Murai, Takahiro Kodama, Kazuki Maesaka, Shoichiro Tange, Daisuke Motooka, Yutaka Suzuki, Yasuyuki Shigematsu, Kentaro Inamura, Yoshihiro Mise, Akio Saiura, Yoshihiro Ono, Yu Takahashi, Yota Kawasaki, Satoshi Iino, Shogo Kobayashi, Masashi Idogawa, Takashi Tokino, Tomomi Hashidate‐Yoshida, Hideo Shindou, Masanori Miyazaki, Yasuharu Imai, Satoshi Tanaka, Eiji Mita, Kazuyoshi Ohkawa, Hayato Hikita, Ryotaro Sakamori, Tomohide Tatsumi, Hidetoshi Eguchi, Eiichi Morii, Tetsuo Takehara   +29 more
wiley   +1 more source

Recent progress in cadonilimab research for oncology applications. [PDF]

Front Immunol
Dong MZ, Cui M, Zhu EB, Lin MQ, Dong GH, Jin GL, Qu LZ, Che HY, Guan HJ.   +8 more
europepmc   +1 more source

Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3‐Mutated AML: A FILO‐DATAML‐PETHEMA Real‐World Study

American Journal of Hematology, EarlyView.
ABSTRACT The addition of midostaurin (MIDO) to intensive chemotherapy (IC) improves survival in younger adults with FLT3‐mutated acute myeloid leukemia (AML); however, real‐world data in elderly patients (≥ 60 years) are limited. This large, retrospective, multicenter study from three European registries (PETHEMA, FILO, DATAML) evaluated MIDO+IC (n ...
Gaspar Aspas Requena, Pau Montesinos, Emilie Bérard, Sarah Bertoli, Rebeca Rodríguez‐Veiga, Celestine Simand, Laura Torres, Pierre Peterlin, Mar Tormo, Rudy Birsen, Juan Miguel Bergua‐Burgues, Emmanuelle Tavernier, Teresa Bernal del Castillo, Martin Carré, Cristina Gil, Adrien Contejean, Eduardo Rodríguez‐Arbolí, Corentin Orvain, Carlos Rodríguez‐Medina, Lauren Veronese, Maria Jose Sayas Lloris, Eric Delabesse, Josefina Serrano, Ariane Mineur, María García‐Fortes, Romain Guieze, Maria Luz Amigo, Arnaud Pigneux, Lorenzo Algarra Algarra, Christian Recher, Pierre‐Yves Dumas, David Martínez‐Cuadrón   +31 more
wiley   +1 more source

Emerging strategies for durable Pt catalysts in PEMFCs. [PDF]

Chem Sci
Chen Y, Meng L, Sun H, Lin H, Sun S.
europepmc   +1 more source

Menin Inhibition in Acute Myeloid Leukemia: Pathobiology, Progress and Promise. [PDF]

Biomedicines
Joshi U, Shallis RM.
europepmc   +1 more source

Zipalertinib-A Novel Treatment Opportunity for Non-Small Cell Lung Cancers with Exon 20 Insertions and Uncommon EGFR Mutations. [PDF]

Cancers (Basel)
Dempke WCM, Fenchel K, Reinmuth N.
europepmc   +1 more source

The efficacy and safety of tislelizumab combined with weekly nab-paclitaxel, carboplatin, and cetuximab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a real-world study. [PDF]

Front Immunol
Ouyang Z, Zhang L, Wang F, Chen M, Cheng B, Yang F, Lai W, Gao J, Wang S, Tong G.   +9 more
europepmc   +1 more source